Mogrify Raises $17 Million to Advance Reprogrammed Cell Therapies  

U.K. biotech Mogrify, which is focused on novel cell-based and in vivo reprogramming for novel therapeutic applications, raised $17 million to close a series A financing round totaling $33 million.

Photo: Darrin Disley, CEO of Mogrify

Parkwalk Advisors led the second close with additional funding from Astellas Venture Management, 24Haymarket, co-founder of Abcam, Jonathan Milner, and Mogrify CEO Darrin Disley.

Mogrify aims to transform the development of ex vivo cell therapies and pioneer a new class of in vivo reprogramming therapies. Proceeds from the financing will be used to advance Mogrify’s immuno-oncology and ophthalmology programs, inclusive of iPSC-derived allogeneic cell therapies targeting hematological and solid malignancies, as well as in vivo reprogramming therapies aiming to address retinal degeneration, a leading cause of blindness, through pre-clinical development.

Mogrify’s technology enables the transformation of any human cell type into any other human cell type. This transformation is achieved using transcription factors or small molecules identified using proprietary big data technologies to enable systematic identification of the key transcriptomic and epigenetic cell switches that drive the speed, efficiency, and maintenance of cellular reprogramming. In addition to the company’s core programs, the broad potential of its technologies allows continued exploration and generation of novel cell-based and in vivo reprogramming therapies for disease areas with high unmet clinical need.

“This latest funding will provide runway toward a significant Series B round as we progress our lead assets toward the clinic,” said Disley.

Author: Rare Daily Staff